β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models

Antimicrobial Agents and Chemotherapy
Jordan R SmithMichael J Rybak

Abstract

Enterococcus faecalis and Enterococcus faecium are frequently resistant to vancomycin and β-lactams. In enterococcal infections with reduced glycopeptide susceptibility, combination therapy is often administered. Our objective was to conduct pharmacokinetic/pharmacodynamic (PK/PD) models to evaluate β-lactam synergy with daptomycin (DAP) against resistant enterococci. One E. faecalis strain (R6981) and two E. faecium strains (R6370 and 8019) were evaluated. DAP MICs were obtained. All strains were evaluated for response to LL37, an antimicrobial peptide, in the presence and absence of ceftaroline (CPT), ertapenem (ERT), and ampicillin (AMP). After 96 h, in vitro models were run simulating 10 mg DAP/kg body weight/day, 600 mg CPT every 8 h (q8h), 2 g AMP q4h, and 1 g ERT q24h, both alone and in combination against all strains. DAP MICs were 2, 4, and 4 μg/ml for strains R6981, R6370, and 8019, respectively. PK/PD models demonstrated bactericidal activity with DAP-CPT, DAP-AMP, and DAP-ERT combinations against strain 8019 (P < 0.001 and log10 CFU/ml reduction of >2 compared to any single agent). Against strains R6981 and R6370, the DAP-AMP combination demonstrated enhancement against R6370 but not R6981, while the combinations of...Continue Reading

References

Oct 1, 1991·Antimicrobial Agents and Chemotherapy·B R MeyersS Z Hirschman
Sep 1, 1995·Antimicrobial Agents and Chemotherapy·J L MainardiF W Goldstein
Mar 1, 1996·The Journal of Antimicrobial Chemotherapy·N Tsuchimori, K Okonogi
Sep 16, 1998·Antimicrobial Agents and Chemotherapy·J TurnerR I Lehrer
Apr 17, 2001·Antimicrobial Agents and Chemotherapy·L B RiceS D Rudin
Jan 5, 2002·Expert Opinion on Investigational Drugs·I Odenholt
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·A K MajumdarJ D Rogers
Oct 24, 2002·Archives of Internal Medicine·Yehuda CarmeliMatthew Samore
Mar 26, 2003·Antimicrobial Agents and Chemotherapy·Barry H DvorchikRobert D Arbeit
Jun 1, 2006·The Journal of Antimicrobial Chemotherapy·Matthew E FalagasKonstantinos Z Vardakas
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Jul 25, 2007·The Journal of Biological Chemistry·Jean-Luc MainardiMichel Arthur
Aug 11, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Kayoko HayakawaKeith S Kaye
Sep 12, 2012·Antimicrobial Agents and Chemotherapy·M Sierra-HoffmanJ Mohr
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Feb 9, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nuria Fernández-HidalgoAlbert Pahissa
Mar 19, 2013·Expert Opinion on Pharmacotherapy·Eric Senneville, Sophie Nguyen
May 22, 2013·Antimicrobial Agents and Chemotherapy·George SakoulasFadi Haddad
Jun 19, 2013·Antimicrobial Agents and Chemotherapy·Anthony M CasapaoMichael J Rybak
Aug 10, 2013·The Journal of Antimicrobial Chemotherapy·Ravina KullarMichael J Rybak
Sep 26, 2013·Antimicrobial Agents and Chemotherapy·Xavier HenryBernard Joris
Oct 5, 2013·Clinical Microbiology Reviews·Romney M HumphriesGeorge Sakoulas
Dec 4, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·George SakoulasVictor Nizet
Dec 24, 2013·Diagnostic Microbiology and Infectious Disease·John EdelsbergDavid J Weber
Dec 25, 2013·Antimicrobial Agents and Chemotherapy·George SakoulasVictor Nizet
May 13, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·E O BillingtonM D Parkins
May 29, 2014·Antimicrobial Agents and Chemotherapy·Lorena DiazCesar A Arias
Jun 4, 2014·International Journal of Antimicrobial Agents·Chun-Hsing LiaoPo-Ren Hsueh
Jun 18, 2014·Antimicrobial Agents and Chemotherapy·Bruk MensaWilliam F DeGrado

❮ Previous
Next ❯

Citations

Jun 30, 2015·Future Microbiology·J M PericásJ M Miró
May 22, 2016·Infectious Disease Clinics of North America·William R MillerCesar A Arias
Oct 27, 2015·Annals of the New York Academy of Sciences·Truc T TranCesar A Arias
May 27, 2016·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Jonathan Hand, Gopi Patel
Jun 8, 2018·Expert Opinion on Pharmacotherapy·Nicholas J MercuroErica S Herc
Sep 7, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lindsay M AveryDavid P Nicolau
May 24, 2019·Current Infectious Disease Reports·German A ContrerasCesar A Arias
Jul 3, 2019·BioMed Research International·Yang YeShufang Liang
Aug 21, 2019·Infectious Diseases and Therapy·Maddalena PeghinMatteo Bassetti
Feb 6, 2021·Pathogens·Gustavo Henrique Rodrigues Vale de MacedoLuís Cláudio Nascimento da Silva
Jun 3, 2021·Antibiotics·Kylen E Ridyard, Joerg Overhage

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.